Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) announced on Friday that its partner Eisai Co Ltd (TYO:4523) has reported Leqembi (lecanemab) sales of JPY13.3bn for the fourth quarter of 2024, corresponding to the third quarter of Eisai's fiscal year ending March 2025.

As a result, BioArctic earned SEK96.7m in royalties, marking a more than tenfold increase from Q4 2023 and a 38% rise from Q3 2024.

Leqembi, developed through a collaboration between BioArctic and Eisai, is a monoclonal antibody targeting amyloid-beta in Alzheimer's disease. Eisai leads clinical development, regulatory approvals and commercialisation, while BioArctic retains co-commercialisation rights in the Nordic region.

The drug is approved in key markets including the United States, Japan, China and Great Britain for mild cognitive impairment and early-stage Alzheimer's disease. A supplemental Biologics License Application for less frequent intravenous dosing was approved by the US Food and Drug Administration in January 2025.

Additionally, the FDA has accepted a rolling submission for a subcutaneous auto-injection formulation, with a decision expected by 31 August 2025.

(EUR1=JPY157.90/SEK11.29)